Skip to content
10-K

Annual Report

Cue Biopharma, Inc. CUE

0001193125-26-108287

← back to feed
Filed
Mar 16, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 13, 2026 97.66M sh
Shares Diluted FY 2025 · Dec 31, 2025 94.73M sh
Shares Diluted FY 2025 · Dec 31, 2024 56.33M sh
Capex FY 2025 · Dec 31, 2025 $177K
Capex FY 2025 · Dec 31, 2024 $66K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$21.69M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$36.33M
Cash And Equivalents FY 2025 · Dec 31, 2025 $27.14M
Cash And Equivalents FY 2025 · Dec 31, 2024 $22.46M
Stockholders Equity FY 2025 · Dec 31, 2025 $26.43M
Stockholders Equity FY 2025 · Dec 31, 2024 $17.5M
Stockholders Equity FY 2025 · Dec 31, 2023 $37.09M
Current Liabilities FY 2025 · Dec 31, 2025 $13.49M
Current Liabilities FY 2025 · Dec 31, 2024 $13.69M
Total Liabilities FY 2025 · Dec 31, 2025 $15.78M
Total Liabilities FY 2025 · Dec 31, 2024 $14.69M
Current Assets FY 2025 · Dec 31, 2025 $36.98M
Current Assets FY 2025 · Dec 31, 2024 $25.14M
Total Assets FY 2025 · Dec 31, 2025 $42.21M
Total Assets FY 2025 · Dec 31, 2024 $32.19M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.28
Eps Diluted FY 2025 · Dec 31, 2024 −$0.72
Eps Basic FY 2025 · Dec 31, 2025 −$0.28
Eps Basic FY 2025 · Dec 31, 2024 −$0.72
Sga Expense FY 2025 · Dec 31, 2025 $16.24M
Sga Expense FY 2025 · Dec 31, 2024 $14.59M
Rd Expense FY 2025 · Dec 31, 2025 $37.74M
Rd Expense FY 2025 · Dec 31, 2024 $36.3M
Net Income FY 2025 · Dec 31, 2025 −$26.6M
Net Income FY 2025 · Dec 31, 2024 −$40.67M
Operating Income FY 2025 · Dec 31, 2025 −$26.55M
Operating Income FY 2025 · Dec 31, 2024 −$41.5M
Revenue FY 2025 · Dec 31, 2025 $27.47M
Revenue FY 2025 · Dec 31, 2024 $9.29M